Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney

R. Brubel, G. Horvath, D. Reglodi, A. Lubics, A. Tamás, P. Kiss, E. Laszlo, J. Németh, L. Márk, P. Szakaly

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP), a multifunctional neuropeptide, has 2 active forms, PACAP38 and PACAP27. It is now well-established that PACAP has several actions also in peripheral organs, including renoprotective effects. The peptide itself has not been previously identified in the rat kidney. The first aim of our study was to identify PACAP in the rat kidney using mass spectrometry and radioimmunoassay (RIA). Receptor mRNA and binding studies revealed the existence of all 3 PACAP receptors (PAC1, VPAC1, and VPAC2) in the kidney, but their exact localization in histologic sections was not evident. Because most of the cytoprotective effects of PACAP relate to its specific PAC1 receptor, our second aim was to identify the cell types wherein the PAC1 receptor is expressed in the rat kidney. Mass spectrometry revealed the presence of PACAP38 in the kidney. RIA measurements showed both PACAP38- and PACAP27-like immunoreactivities in kidney homogenates, with PACAP38 being dominant. Immunohistochemistry revealed PAC1 receptor-like immunoreactivity in kidney sections, mainly expressed in cortical tubular epithelial cells. These results showed PACAP to be endogenously present in the kidney. The tubular localization of the PAC1 receptor provides the basis for the renal effects of the peptide under physiologic and pathologic conditions.

Original languageEnglish
Pages (from-to)1297-1299
Number of pages3
JournalTransplantation Proceedings
Volume43
Issue number4
DOIs
Publication statusPublished - May 2011

Fingerprint

Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
Pituitary Adenylate Cyclase-Activating Polypeptide
Kidney
Radioimmunoassay
Mass Spectrometry
Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
Peptides
Neuropeptides

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney. / Brubel, R.; Horvath, G.; Reglodi, D.; Lubics, A.; Tamás, A.; Kiss, P.; Laszlo, E.; Németh, J.; Márk, L.; Szakaly, P.

In: Transplantation Proceedings, Vol. 43, No. 4, 05.2011, p. 1297-1299.

Research output: Contribution to journalArticle

@article{efc4688204aa40e58cfbd7a73a3b5172,
title = "Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney",
abstract = "Pituitary adenylate cyclase activating polypeptide (PACAP), a multifunctional neuropeptide, has 2 active forms, PACAP38 and PACAP27. It is now well-established that PACAP has several actions also in peripheral organs, including renoprotective effects. The peptide itself has not been previously identified in the rat kidney. The first aim of our study was to identify PACAP in the rat kidney using mass spectrometry and radioimmunoassay (RIA). Receptor mRNA and binding studies revealed the existence of all 3 PACAP receptors (PAC1, VPAC1, and VPAC2) in the kidney, but their exact localization in histologic sections was not evident. Because most of the cytoprotective effects of PACAP relate to its specific PAC1 receptor, our second aim was to identify the cell types wherein the PAC1 receptor is expressed in the rat kidney. Mass spectrometry revealed the presence of PACAP38 in the kidney. RIA measurements showed both PACAP38- and PACAP27-like immunoreactivities in kidney homogenates, with PACAP38 being dominant. Immunohistochemistry revealed PAC1 receptor-like immunoreactivity in kidney sections, mainly expressed in cortical tubular epithelial cells. These results showed PACAP to be endogenously present in the kidney. The tubular localization of the PAC1 receptor provides the basis for the renal effects of the peptide under physiologic and pathologic conditions.",
author = "R. Brubel and G. Horvath and D. Reglodi and A. Lubics and A. Tam{\'a}s and P. Kiss and E. Laszlo and J. N{\'e}meth and L. M{\'a}rk and P. Szakaly",
year = "2011",
month = "5",
doi = "10.1016/j.transproceed.2011.03.081",
language = "English",
volume = "43",
pages = "1297--1299",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney

AU - Brubel, R.

AU - Horvath, G.

AU - Reglodi, D.

AU - Lubics, A.

AU - Tamás, A.

AU - Kiss, P.

AU - Laszlo, E.

AU - Németh, J.

AU - Márk, L.

AU - Szakaly, P.

PY - 2011/5

Y1 - 2011/5

N2 - Pituitary adenylate cyclase activating polypeptide (PACAP), a multifunctional neuropeptide, has 2 active forms, PACAP38 and PACAP27. It is now well-established that PACAP has several actions also in peripheral organs, including renoprotective effects. The peptide itself has not been previously identified in the rat kidney. The first aim of our study was to identify PACAP in the rat kidney using mass spectrometry and radioimmunoassay (RIA). Receptor mRNA and binding studies revealed the existence of all 3 PACAP receptors (PAC1, VPAC1, and VPAC2) in the kidney, but their exact localization in histologic sections was not evident. Because most of the cytoprotective effects of PACAP relate to its specific PAC1 receptor, our second aim was to identify the cell types wherein the PAC1 receptor is expressed in the rat kidney. Mass spectrometry revealed the presence of PACAP38 in the kidney. RIA measurements showed both PACAP38- and PACAP27-like immunoreactivities in kidney homogenates, with PACAP38 being dominant. Immunohistochemistry revealed PAC1 receptor-like immunoreactivity in kidney sections, mainly expressed in cortical tubular epithelial cells. These results showed PACAP to be endogenously present in the kidney. The tubular localization of the PAC1 receptor provides the basis for the renal effects of the peptide under physiologic and pathologic conditions.

AB - Pituitary adenylate cyclase activating polypeptide (PACAP), a multifunctional neuropeptide, has 2 active forms, PACAP38 and PACAP27. It is now well-established that PACAP has several actions also in peripheral organs, including renoprotective effects. The peptide itself has not been previously identified in the rat kidney. The first aim of our study was to identify PACAP in the rat kidney using mass spectrometry and radioimmunoassay (RIA). Receptor mRNA and binding studies revealed the existence of all 3 PACAP receptors (PAC1, VPAC1, and VPAC2) in the kidney, but their exact localization in histologic sections was not evident. Because most of the cytoprotective effects of PACAP relate to its specific PAC1 receptor, our second aim was to identify the cell types wherein the PAC1 receptor is expressed in the rat kidney. Mass spectrometry revealed the presence of PACAP38 in the kidney. RIA measurements showed both PACAP38- and PACAP27-like immunoreactivities in kidney homogenates, with PACAP38 being dominant. Immunohistochemistry revealed PAC1 receptor-like immunoreactivity in kidney sections, mainly expressed in cortical tubular epithelial cells. These results showed PACAP to be endogenously present in the kidney. The tubular localization of the PAC1 receptor provides the basis for the renal effects of the peptide under physiologic and pathologic conditions.

UR - http://www.scopus.com/inward/record.url?scp=79957587817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957587817&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.03.081

DO - 10.1016/j.transproceed.2011.03.081

M3 - Article

C2 - 21620115

AN - SCOPUS:79957587817

VL - 43

SP - 1297

EP - 1299

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -